Apimeds Pharmaceuticals US Inc(APUS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 3:55 PM ET (Korea 10/27 04:55)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -36.71 | Insider Own | 62.68% | Shs Outstand | 1.5M | Perf Week | -17.29% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.6M | Perf Month | -60.07% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 2.82% | Short Float | 14.2% | Perf Quarter | -63.81% |
| Income | -0.06B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.02 | Perf Half Y | -84.6% |
| Sales | 0.00B | P/B | 0.04 | EPS next 5Y | - | ROA | -84.2% | Short Interest | 0.08M | Perf YTD | -82.35% |
| Book/sh | 70.54 | P/C | 0.53 | EPS past 3/5Y | -108.46% - | ROE | -100.13% | 52W High | -95.15% ($59.70) | Perf Year | -85.38% |
| Cash/sh | 5.48 | P/FCF | - | Sales past 3/5Y | - | ROIC | -54.59% | 52W Low | 91.72% ($1.51) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1063.72% | Gross Margin | - | Volatility(W/M) | 12.3% 23.04% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.51 | EPS Q/Q | -456.18% | Profit Margin | - | RSI (14) | 40.95 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.51 | Sales Q/Q | - | SMA20 | -34.63% ($4.42) | Beta | 0.05 | Target Price | - |
| Payout | - | Debt/Eq | 0.14 | Earnings | - | SMA50 | -23.66% ($3.79) | Rel Volume | 0.01 | Prev Close | $2.89 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -73.99% ($11.11) | Avg Volume(3M) | 3.70M | Price | $2.89 |
| IPO | 2025/5/9 | Option/Short | No/Yes | Trades | 924 | Volume | 29,827 | Change | 0.17% |
A clinical-stage biopharmaceutical company developing non-opioid, biology-based pain management therapies. The company went public on the NYSE in May 2025 and is advancing a pipeline that includes Apitox, a honeybee venom–based treatment targeting knee osteoarthritis and neuroinflammatory conditions.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
APUS has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #76 of 83 in the industry
Based on market cap of $4M.
SNOA#74 Sonoma Pharmaceuticals Inc $5M PER - 
GELS#75 Gelteq Ltd $5M PER - APUS#76 Apimeds Pharmaceuticals US Inc $4M PER - 
YCBD#77 cbdMD Inc $4M PER - 
RDHL#78 Redhill Biopharma Ltd ADR $4M PER - 
FAQ
What kind of company is APUS?
APUS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of APUS?
The market cap of APUS is approximately $4M, ranking 5,651 within its sector.
What is the 52-week high and low for APUS?
APUS has recorded a 52-week high of $59.70 and a low of $1.51.
